Biosimilar Battlefield: Samsung Bioepis Forecast
This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...
515 Views
Surveying The Biosimilar Battlefield
The biosimilar market has been of particular interest to us in light of the high expectations set for Samsung Biologics Co., Ltd (207940 KS) and...
704 Views
Celltrion Has Potential Manufacturing Headaches
A Form 483 from the USFDA (attached) that criticizes aspects of Celltrion Inc (068270 KS)'s manufacturing facility in Incheon has surfaced in the...
484 Views
Reconsider the Samsung Bioepis Valuation
As noted in our Insight Pass on the Deal, Put on the Watchlist one of the underpinnings of the valuation of Samsung Biologics Co., Ltd (207940 KS)...
769 Views
US Healthcare Overhaul Stumbling, Singapore Cyclical Rally Looking Premature
The Republican replacement for ‘Obamacare’ has been announced and looks an incoherent mess – resurgent healthcare inflation will be a drag on...
1.6k Views